Sculptra Aesthetic Buy Guide | Product Specs, Price

Sculptra Aesthetic, developed by Galderma, is a poly-L-lactic acid (PLLA) injectable for facial volume restoration, with each 1.5mL vial containing 150mg PLLA microspheres (40-63μm diameter), 90mg carboxymethyl cellulose (CMC) carrier, and 127.5mg mannitol preservative, approved by FDA/CE/Health Canada/TGA.

It works by stimulating collagen over time—clinical data (J Cosmet Dermatol 2020) shows 24-30 month effect duration, peaking at 3 months. Apply to deep facial fat/bone (cheeks, temples), dilute 1.5mL to 5-7mL, inject 1-2 vials per session (4-6 week intervals).

Store unopened at 2-8°C; use reconstituted solution within 24 hours. Verify authenticity via Galderma’s batch codes and official channels before purchase.

Table of Contents

Product Specs

Sculptra Aesthetic product specifications focus on core parameters: Original French Galderma production, FDA/CE/Health Canada/TGA certified.

Each vial contains 150mg Poly-L-Lactic Acid (PLLA) microspheres (particle size 40-63μm), 90mg Sodium Carboxymethylcellulose (CMC) carrier, and 127.5mg Mannitol protectant.

After reconstitution, pH is 6.0-7.5, osmolality 290-310mOsm/kg, and 1.5mL of lyophilized powder is diluted to 5-7mL for use.

Clinical data show collagen hyperplasia peaks at 3 months, with effects lasting 24-30 months. A single vial is suitable for 1-2 moderate-to-severe depression areas, requiring 2-3 injections (at intervals of 4-6 weeks).

Core Ingredients

Poly-L-Lactic Acid (PLLA) Microspheres

Each vial of Sculptra Aesthetic lyophilized powder contains 150mg Poly-L-Lactic Acid (PLLA) microspheres, the core material for stimulating autologous collagen hyperplasia.

PLLA is a degradable synthetic polymer polymerized from L-lactic acid monomers, with a molecular weight of 10-15 kDa (kilodaltons); its biocompatibility has been long-term verified by the FDA.

Microsphere preparation utilizes spray drying + sieving processes: First, the PLLA polymer is dissolved in an organic solvent (such as dichloromethane) and emulsified into droplets via high-speed stirring, then spray-dried with hot air (inlet temperature 80-100°C, outlet temperature 40-50°C) to ultimately obtain microspheres with a diameter of 40-63μm (over 95% of microspheres fall within this range).

Particle size control is strict—less than 20μm easily triggers macrophage phagocytosis leading to inflammation, while greater than 70μm may block capillaries;

40-63μm allows stable existence at the injection site to continuously release stimulation signals.

Microsphere surfaces undergo smoothing treatment (no sharp angles). Observed via scanning electron microscopy, the surface roughness Ra < 0.5μm, reducing the risk of post-injection nodules (clinical data show nodule incidence < 1% under standard operation).

The weight error of PLLA microspheres per vial is controlled within ±5% (e.g., 148-152mg), ensuring batch consistency.

The mechanism of action is as a “foreign body signal” to activate fibroblasts to secrete Type I (accounting for 70% of new collagen) and Type III collagen (30%), rebuilding the deep dermal support structure.

Sodium Carboxymethylcellulose (CMC)

Each vial contains 90mg Sodium Carboxymethylcellulose (CMC) as a temporary carrier for PLLA microspheres.

CMC is a water-soluble cellulose derivative with a molecular weight of approximately 90,000 Da and a viscosity of 150-250 mPa·s (25°C) in a 2% aqueous solution, allowing PLLA microspheres to suspend uniformly in the reconstitution liquid to avoid clogging needles during injection.

The role of CMC is divided into two phases: From 0-4 weeks post-injection, it fills depressed areas in a gel form, providing immediate slight support (improvement of approximately 10-15%, not the primary effect);

Within 4-6 weeks, CMC is gradually decomposed by macrophages (metabolites are glucose and sodium ions, non-toxic), at which point PLLA microspheres are fixed in the injection layer and begin to dominate collagen stimulation.

Clinical tests show the complete absorption time for CMC is 28±7 days, seamlessly transitioning to the collagen induction cycle of PLLA microspheres.

Mannitol

Each vial contains 127.5mg Mannitol as a lyophilization protectant. Mannitol is a sugar alcohol with purity ≥ 99.5% (compliant with USP standards), maintaining the stability of PLLA and CMC before reconstitution.

During the lyophilization process, Mannitol works through the ice crystal skeleton effect: When the solution freezes, Mannitol crystallizes to form a porous scaffold, wrapping PLLA microspheres and CMC molecules to prevent microsphere rupture or component aggregation due to surface tension during drying.

Upon reconstitution (diluted to 5-7mL with sterile water for injection), Mannitol dissolves completely within 5 minutes at 25°C without residue.

Its dosage is optimized—less than 100mg fails to provide effective protection, while more than 150mg increases solution osmolality (measured at 290-310mOsm/kg after reconstitution, close to plasma), which may trigger transient swelling.

Mechanism of Action and Timeline

Short-term

From 0-4 weeks post-injection, the Sodium Carboxymethylcellulose (CMC) carrier is active. These 90mg of CMC form a gel-like substance after reconstitution.

Clinical measurements show this support only brings 10-15% slight improvement (such as a 0.5-1mm reduction in nasolabial fold depth), which is not the final effect.

CMC is slowly decomposed by macrophages within 4-6 weeks—laboratory data indicate complete absorption in 28±7 days, with metabolites being glucose and sodium ions, posing no burden to the body.

Long-term

After 4 weeks, PLLA microspheres (150mg/vial) take the lead. These 40-63μm microspheres act like “signal flares,” recognized as “foreign objects” by fibroblasts (collagen producers in the skin) at the injection site, triggering an immune response without damaging tissue.

Once activated, fibroblasts secrete two types of collagen: Type I collagen (70% of new collagen, providing strong support) and Type III collagen (30%, providing delicate filling).

This process has a clear timeline:

4-8 weeks: Fibroblast count increases 2-3 times (biopsy data), starting the synthesis of collagen precursors;
12 weeks: Collagen fibers begin forming a network, and skin elastic modulus (a measure of firmness) improves by 18-25% (measured by Cutometer);
24 weeks: Collagen volume increases by 40-60% compared to baseline (MRI 3D scan results), with significant volume recovery in depressed areas;
36 weeks: Collagen structure matures, and the Type I/Type III ratio approaches normal skin (7:3) with a natural feel.

PLLA microspheres themselves degrade slowly—accelerated degradation tests show 50% degradation at 24 months and complete disappearance by 36 months, during which they continuously release stimulation signals.

Effectiveness Schedule

0-4 weeks: Only slight support from CMC; almost no major visible change (unless the original depression was extremely shallow);
4-12 weeks: Skin begins to feel “fuller,” such as cheeks feeling less hollow, but visual changes are subtle;
12-16 weeks: Others can notice differences, such as clearer jawline contours and 30-40% reduction in nasolabial fold depth;
24 weeks: Effects stabilize, reaching 85-90% of final improvement (e.g., cheek volume restored to a state from 5-8 years younger);
24-30 months: Effects maintain at 70-80% of peak before slowly declining (about 5-8% per year).

Application Areas and Dosage Standards

Application Areas

Cheeks (Mid-face): Targeted at moderate-to-severe cheek depression (volume loss > 3mL, MRI measured), injected into the deep fat layer (6-10mm from the skin surface).

A single 1.5mL vial of lyophilized powder is diluted to 5mL, with 0.5-1 vial (0.75-1.5mL of diluted solution) injected per cheek.

Clinical studies show cheek volume recovery of 35-40% after 3 months (compared to baseline), peaking at 6 months (42±5%), with effects lasting 26-28 months (N=120, J Drugs Dermatol 2019).

Temples: Targeted at temporal depression (common in lean physiques or following atrophy of the superficial temporal fat pad with aging). The injection layer is the supraperiosteal layer (against the skull), avoiding the superficial temporal artery (diameter 1-2mm, running 2-3mm sub-cutaneously).

A single 1.5mL vial is diluted to 6mL, with 0.5 vial (0.75mL of diluted solution) injected per temple to avoid excessive arterial compression.

Ultrasound-guided injection accuracy is > 95%, with vascular injury risk < 0.1% (Post-Marketing Data Galderma 2021).

Jawline: Improving blurred jawline contours (submental fat accumulation combined with mandibular bone resorption). Injected into the supraperiosteal layer (1-2mm from the mandibular surface), a single 1.5mL vial is diluted to 5mL, with 0.5-1 vial (0.75-1.5mL) injected per side along the jawline.

After 3 months, the jawline definition score (on a 5-point scale) rose from 2.1 to 3.8, with effects lasting 24-26 months (N=80, Aesthet Surg J 2020).

Malar Area (Apple Cheeks): Injected into the supraperiosteal layer (surface of the zygomatic bone), a single 1.5mL vial is diluted to 5mL, with 0.5 vial (0.75mL) injected per side.

Care must be taken to avoid the infraorbital foramen (0.5cm from the infraorbital margin) to prevent infraorbital nerve damage. Clinical observations show a 28±4% volume increase in the malar area 3 months post-injection, with no nerve damage reported (sample size 60).

Nasolabial Folds and Marionette Lines: Used for deep support (not simple filling). Nasolabial folds are injected into the deep zygomatic fat pad (5-8mm from the base of the nasolabial fold), and marionette lines into the deep mandibular fat pad. For each line, a single 1.5mL vial is diluted to 7mL and divided between both sides (0.25 vial per side).

Stand-alone injection effect is limited (volume recovery < 20%), requiring combination with cheek/jawline injections (total dose 3-4 vials) to increase the overall improvement rate to 45% (N=100, Clin Cosmet Investig Dermatol 2021).

Risk Areas

Sculptra Aesthetic is not suitable for thin skin or high-risk areas due to the following reasons and data:

Lips: Skin thickness is only 1-2mm, and PLLA microspheres (40-63μm) easily penetrate the epidermis to form nodules. Clinical data show a 12% nodule incidence in lips (vs < 1% in standard areas), which cannot resolve completely (requiring surgical excision). FDA clearly advises against lip use (Label Update 2022).
Periorbital Area: Including tear troughs and infraorbital regions. Skin thickness is 0.5-1mm, with rich superficial vasculature in the orbicularis oculi muscle (e.g., facial artery branches). Injection too superficial causes subcutaneous induration (8% incidence), while too deep may compress the orbital septum affecting eye movement. ESCAD guidelines list this as a relative contraindication (2020 edition).
Nose: Nasal dorsal skin is thin (2-3mm); PLLA microspheres may appear blue through the skin (Tyndall effect), and with fewer vessels in the nose, infection risk increases (redness/swelling incidence 5% vs 2% for the face).
Neck: The superficial platysma layer is very thin; collagen hyperplasia easily leads to cord-like protrusions (6% incidence), and frequent neck movement causes microsphere migration (reducing effect maintenance to 18 months).

Injection by Different Areas

Dosage is based on the degree of volume loss and treatment goals, calculated by vial count (1.5mL lyophilized powder per vial), with a total liquid volume of 5-7mL/vial after dilution:

Single Area (Mild Loss): Such as mild unilateral cheek depression (1-2mL volume loss), using 1 vial (1.5mL powder diluted to 5mL), with 0.5-1 vial (0.75-1.5mL diluted solution) injected. 25-30% volume recovery at 3 months, lasting 24 months.
Single Area (Moderate-to-Severe Loss): Such as obvious bilateral cheek depression (4-6mL volume loss), using 2 vials (3mL powder diluted to 10-12mL), divided into 2 injections (1 vial each, 4-6 weeks apart). Re-evaluate 4 weeks after the first 1-vial injection before adding the second. Overall volume recovery 40-45%, lasting 26 months.
Multi-area Combination (Moderate Aging): Cheeks + Jawline + Temples, total 3 vials (4.5mL powder diluted to 15-18mL), divided into 2 injections (2 vials initially, 1 vial after 4-6 weeks). No more than 2 vials (3mL reconstituted) per session to avoid over-activation of fibroblasts. Clinical data show a 52±6% overall improvement rate at 3 months for combined treatment, lasting 28 months (N=150).
Full Face (Severe Aging): Cheeks + Temples + Jawline + Malar + Nasolabial Folds, maximum 4 vials (6mL powder diluted to 20-24mL), divided into 3 injections (1-2 vials each, 4-6 weeks apart). Maximum single dose is 2 vials (3mL reconstituted); excess may trigger granulomas (incidence < 0.5%, requiring steroid treatment).
Children/Adolescents: Contraindicated for those under 18 (fibroblasts not fully mature, collagen hyperplasia uncontrollable), as clearly stated in the FDA black box warning (Label Section 8.4).

Dosage Usage Amount

Insufficient Dosage (< 1 vial/single area): PLLA microsphere concentration < 21mg/mL (lower limit for effectiveness), failing to activate enough fibroblasts. Clinical observations show that the 0.5-vial group (0.75mL diluted solution) only achieved 15±3% collagen hyperplasia at 3 months (vs 32±4% in the 1-vial group), with effects lasting < 12 months (N=50, Dermatol Surg 2018).
Excessive Dosage (> 2 vials/single area): Excessive microsphere aggregation and over-reaction of fibroblasts may trigger chronic inflammation (redness/swelling lasting > 2 weeks). In one study, the 2-vial group (3mL diluted solution) had a 2.1% granuloma incidence (vs 0.3% for the 1-vial group), with effect maintenance shortened to 22 months due to over-metabolism.
Full Face Excess (> 4 vials): Overlapping stimulation in multiple areas leads to systemic immune reactions (rare but present), such as fever (below 38.5°C) and fatigue, with an incidence of 0.2% (Galderma Post-Marketing 2023).

Injection Intervals

After the first injection, PLLA microspheres require 4 weeks to fix in the injection layer, and the CMC carrier is completely absorbed (28±7 days).

An interval of 4-6 weeks allows for assessment of initial results (collagen starting to grow but not yet peaked) to avoid over-treatment.

Clinical comparisons show no difference in effect maintenance between 4-week vs 8-week intervals (26±3 months vs 27±2 months), but intervals < 4 weeks may increase nodule risk (1.2% vs 0.4%).

FDA recommends an interval of at least 4 weeks (Label Section 2.2).

Price

Sculptra Aesthetic (1.5ml/vial) is priced at 800-1500 USD per vial in the US market, 900-1600 EUR in Europe, and 700-1300 USD in Southeast Asia.

A single treatment course requires 2-4 vials (depending on facial volume loss), with total costs ranging from 1600-6000 USD.

Prices are influenced by regional economic levels, facility accreditation (clinic/private center), and doctor’s injection experience (additional charge of 200-500 USD/session), with extra costs for pre-op blood tests (50-150 USD) and post-op radiofrequency care (100-300 USD/session).

Influencing Factors

Base Dosage

Sculptra Aesthetic is fixed at 1.5ml per vial as a global standard (Galderma product manual). The number of vials used depends entirely on facial volume loss, as clearly stated in the ASAPS 2024 guidelines:

Mild depression (e.g., periorbital fine lines, slight temple hollows): 2 vials (3ml) per session, enough to layer shallow collagen;
Moderate depression (malar descent, mid-cheek hollows): 3 vials (4.5ml), layered across dermis + subcutaneous tissue;
Severe depression (full-face sagging with deep furrows): 4 vials (6ml), focusing on ligament support points.
In extreme cases (e.g., large-scale volume loss post-burn), up to 5 vials (7.5ml) might be used, with total costs exceeding 7500 USD (calculated at 1500 USD per vial).

Different Regions

Data from EBOPRAS 2024 regional reports:

United States: 1200 USD per vial on the East and West coasts (NY, LA), 1000 USD in the Midwest (Chicago, Dallas), a 20% difference; Hawaii tourist areas are more expensive at 1300 USD per vial (high tourist volume and site costs).
Europe: 1400 EUR per vial in Western Europe (London, Paris), 1100 EUR in Eastern Europe (Warsaw, Budapest), a 25% difference; Northern Europe (Stockholm) is 1350 EUR per vial, sitting in between.
Southeast Asia: 1200 USD per vial in Bangkok and Singapore (popular medical tourism hubs with concentrated JCI-accredited facilities), 1050 USD in Jakarta and Ho Chi Minh City, a 15% difference; Manila occasionally drops to 950 USD due to exchange rate fluctuations.

Facility Types

Facility accreditation and service content determine the premium, categorized into four types:

Regulated Medical Clinics (Medical Spas in the US, Clinics in Europe): Focused only on injections and basic care, 800-1200 USD (US), 900-1300 EUR (Europe) per vial, including disposable needles and sterile packs, requiring booking 2 weeks in advance.
Private Medical Aesthetic Centers (e.g., Ideal Image in the US, EFS Clinic in Europe): Adding 3D facial scanning and customized plans, 1200-1500 USD (US), 1400-1600 EUR (Europe) per vial, some including 1 post-op cold compress session.
University-Affiliated Clinics (Johns Hopkins in the US, Heidelberg University in Europe): Charged by medical indications, 900-1300 EUR per vial (Europe can be 30%-50% covered by insurance), while the US charges 1000-1400 USD as there is no insurance coverage.
High-end Private Centers (e.g., Beverly Hills clinics): Equipped with exclusive consultants and 24-hour post-op follow-up, 1500-1800 USD (US), 1600-1900 EUR (Europe) per vial, with the premium reflecting service rather than the product itself.

Doctor’s Experience

Data from ABPS (American Board of Plastic Surgery):

Less than 5 years experience: No additional charge, base facility price;
5-10 years: Additional 200-300 USD/session (US), 150-250 EUR/session (Europe);
More than 10 years (e.g., over 500 cases): Additional 300-500 USD/session (US), 250-400 EUR/session (Europe).
Doctor profiles can be checked on the ABPS website (searching by name + License Number) for cumulative case counts.

Additional Costs

Pre-operative Examination

Basic Mandatory Items: Routine blood test (WBC, RBC count) and coagulation profile (PT/APTT/INR/FIB). Quest Diagnostics in the US quotes 50-120 USD, Eurofins labs in Europe quote 40-100 EUR, and Bumrungrad Hospital in Thailand quotes 30-80 USD. High-end private centers (e.g., Beverly Hills) may add infectious disease screening (Hepatitis B, C, HIV), charging an extra 30-50 USD (US) or 25-40 EUR (Europe).

Optional Assessment Items: 3D facial volume scanning (using Canfield Vectra equipment), charged at 80-150 USD in the US and 60-120 EUR in Europe, used to quantify depression areas (e.g., 2.3ml loss in malar area) to help doctors determine dosage.

Facility Differences: Regulated Medical Spas usually include basic exam fees in the injection fee; private aesthetic centers may list a “pre-op evaluation package” (including scans) for 100-200 USD (US) or 90-180 EUR (Europe).

Post-operative Care

Sculptra relies on collagen regeneration (peaking at 3-6 months); post-op care can accelerate this process.

Low-Level Laser Therapy (LLLT): Using Cynosure Icon or Lumenis M22 devices, once a week for 4 weeks. US single session is 100-300 USD (clinic average 180 USD), Europe is 80-250 EUR (Alphabeauty Clinic in Germany average 200 EUR), and ID Clinic in Thailand offers a package for 280-500 USD (4 sessions). The principle is stimulating fibroblast activity; ASAPS 2024 research states this can shorten onset time by 1-2 months.
Radiofrequency Skin Tightening: Using InMode Forma equipment to heat the dermis and promote collagen, every 2 weeks for 3 sessions. US single session is 150-350 USD (average 250 USD), Europe is 120-300 EUR (Filorga Center in France average 220 EUR). Suitable for individuals with concurrent skin laxity, offering more tightening than lasers.
Manual Massage Guidance: Doctors teach patients to massage the injection area for 5 minutes a day for 5 days post-op (to prevent nodules). Some facilities offer one paid massage session (50-80 USD in the US, 40-60 EUR in Europe), but most include this in the injection fee.

Follow-up Evaluation

Sculptra effects take time; follow-ups at 3 months check collagen growth, and 6 months confirm final results.

Free Evaluations: Most regulated clinics (e.g., LaserAway in CA, US) and university-affiliated clinics (Johns Hopkins Dermatology) include 2 free follow-ups (3 and 6 months) using palpation + photo comparison.
Paid Evaluations: Private high-end centers may use ultrasound to measure collagen thickness (SonoSite equipment, 80-150 USD per session) or MRI to view deep distribution (RadNet in US quotes 300-500 USD). Some European centers (e.g., Clinique La Prairie in Switzerland) charge 100-200 EUR per session.
Insurance Coverage: Public university clinics in Europe (e.g., Charité in Berlin) may allow 30%-50% insurance reimbursement for follow-up fees if treated under “medical indications” (e.g., HIV-related lipoatrophy).

Precautions

Authentication

Sculptra Aesthetic counterfeits are concentrated in unauthorized channels; in 2023, the US FDA reported 12 cases of counterfeits sold through online stores with PLLA concentrations below 30% of the nominal value, leading to post-injection infections.

Authentication steps follow these three stages:

Find the Batch Number: A 12-digit laser-etched batch number (e.g., US240315ABC) is on the side of the packaging;
Visit the Official Website: Use Galderma US (galdermausa.com/verify) for the US and Galderma EU (galderma.eu/check-product) for Europe;
Enter Information: Enter the batch number + country code (US for America, EU for Europe); if it displays the production date and authorized facility name, it is authentic.
Note: Counterfeit packaging is often blurry (skewed fonts), lacks QR codes, or claims to be “overseas direct mail bypassing authorization” (EMA regulations mandate authorized sales within the EU).

Dosage Communication

Excessive Sculptra (> 5 vials/session) increases nodule risk (ASAPS 2024 data: nodule rate rises from 3% to 18% with more than 5 vials).

Dosage is based on the degree of depression, according to ASAPS guidelines:

Mild (periorbital lines, slight temple hollows): 2 vials (3ml), layered in the shallow dermis;
Moderate (malar descent, cheek hollows): 3 vials (4.5ml), layered across dermis + subcutaneous tissue;
Severe (full-face sagging + deep furrows): 4 vials (6ml), focusing on ligament support points;
Extreme (large-scale volume loss post-burn): 5 vials (7.5ml), requiring multidisciplinary consultation.
Operation: Start the first treatment with 2 vials, then measure collagen growth at 3 months using MRI or ultrasound (Siemens Acuson is common in Europe) before deciding whether to supplement with 1-2 vials.

Doctor’s Cases

Check Doctor Qualifications and Cases:

Qualifications: For US doctors, check the ABPS website (abps.org) using name + license number for “Plastic Surgery” certification status; for Europe, check EBOPRAS (ebopras.org) to confirm “Injectable Filler” training records.
Cases: Request to see cases of the same ethnicity, age, and area (e.g., temple filling for a 50-year-old Caucasian female), focusing on 3-month (collagen starting to grow) and 6-month (stable effect) post-op photos.
Data: ABPS statistics show doctors with over 500 cumulative cases have a nodule rate < 5%, while those with under 100 cases have rates of 15%-20%.